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Abstract: A single male domestic shorthair cat that did not complete puberty was reported. At four
years of age, it still had primary dentition, testicular hypoplasia, and was relatively small for its age.
We hypothesized that the phenotype might have been due to an inherited form of hypogonadotropic
hypogonadism (HH). We sequenced the genome of the affected cat and compared the data to
38 genomes from control cats. A search for private variants in 40 candidate genes associated with
human HH revealed a single protein-changing variant in the affected cat. It was located in the TAC3
gene encoding tachykinin 3, a precursor protein of the signaling molecule neurokinin B, which is
known to play a role in sexual development. TAC3 variants have been reported in human patients with
HH. The identified feline variant, TAC3:c.220G>A or p.(Val74Met), affects a moderately conserved
region of the precursor protein, 11 residues away from the mature neurokinin B sequence. The affected
cat was homozygous for the mutant allele. In a cohort of 171 randomly sampled cats, 169 were
homozygous for the wildtype allele and 2 were heterozygous. These data tentatively suggest that the
identified TAC3 variant might have caused the suppression of puberty in the affected cat.
Keywords: Felis catusL.; whole genome sequence; animal model; neurokinin B; puberty; development;
precision medicine; disorder of sexual development
1. Introduction
Gonadotropin releasing hormone (GnRH) is a main regulator of the reproductive endocrine system.
Its secretion determines the pattern of secretion of luteinizing hormone (LH) and follicle-stimulating
hormone (FSH). LH activates the release of testosterone in Leydig cells in the testicle. Testosterone is
responsible for the male phenotype, body growth, and sperm production [1]. Coordinated and pulsatile
GnRH secretion is induced due to the synergistic action of neurokinin B, kisspeptin, and dynorphin [2].
Neurokinin B stimulates kisspeptin neurons, which leads to GnRH secretion [3]. Dysfunctional GnRH
release leads to low blood testosterone and pituitary hormone levels, resulting in hypogonadotropic
hypogonadism (HH) [4]. Impaired testicular function may occur due to a primary testicular disorder or
secondary to hypothalamic–pituitary dysfunction (hypogonadotropic). HH may be inherited or caused
by non-genetic factors, such as drugs, encephalic trauma, or infiltrative or inflammatory pituitary
lesions. Congenital hypogonadotropic hypogonadism (cHH) is a rare genetic disorder characterized by
a delayed or absent pubertal development, micropenis, cryptorchidism, androgen/estrogen deficiency,
and infertility due to an inadequate secretion of gonadotrophin-releasing hormone (GnRH), with an
otherwise structurally and functionally normal hypothalamus and pituitary gland. Low testosterone
and pituitary hormone levels confirm the diagnosis [4]. Variants in 40 genes have been shown to cause
different inherited forms of HH in humans (Table 1).
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Table 1. Overview on genetic causes of human HH.
Gene Phenotype Inheritance Ref.
CHD7 Hypogonadotropic hypogonadism 5 with or without anosmia AD [5]
DAX1 Adrenal hypoplasia, congenital XLR [6]
DUSP6 Hypogonadotropic hypogonadism 19 with or without anosmia AD [7]
FEZF1 Hypogonadotropic hypogonadism 22 with or without anosmia AR [8]
FGF8 Hypogonadotropic hypogonadism 6 with or without anosmia AD [9]
FGF17 Hypogonadotropic hypogonadism 20 with or without anosmia AD [7]
FGFR1 Hypogonadotropic hypogonadism 2 with or without anosmia AD [10]
FLRT3 Hypogonadotropic hypogonadism 21 with anosmia AD [7]
FSHB Hypogonadotropic hypogonadism 24 without anosmia AR [11]
GNRH1 Hypogonadotropic hypogonadism 12 with or without anosmia AR [12]
GNRHR Hypogonadotropic hypogonadism 7 without anosmia AR [13]
HESX-1 Growth hormone deficiency with pituitary anomalies AR, AD [14]
HS6ST1 Hypogonadotropic hypogonadism 15 with or without anosmia AD [7]
IL17RD Hypogonadotropic hypogonadism 18 with or without anosmia AR, AD [7]
KAL1 Hypogonadotropic hypogonadism 1 with or without anosmia XLR [15]
KISS1 Hypogonadotropic hypogonadism 13 with or without anosmia AR [16]
KISS1R Hypogonadotropic hypogonadism 8 with or without anosmia AR [17]
LEP Obesity, morbid, due to leptin deficiency AR [18]
LEPR Obesity, morbid, due to leptin deficiency AR [18]
LHB Hypogonadotropic hypogonadism 23 with or without anosmia AR [19]
LHX3 Pituitary hormone deficiency, combined, 3 AR [20]
NELF Hypogonadotropic hypogonadism 9 with or without anosmia AD [21]
OTUD4 Gordon Holmes syndrome AR [22]
PNPLA6 Boucher–Neuhauser Syndrome AR [23]
POLR3B hypogonadotropic hypogonadism AR [24]
PROK2 Hypogonadotropic hypogonadism 4 with or without anosmia AD [25]
PROKR2 Hypogonadotropic hypogonadism 3 with or without anosmia AD [25]
PROP-1 Pituitary hormone deficiency, combined, 2 AR [26]
RAB18 Warburg micro syndrome 3 AR [27]
RAB3GAP1 Warburg micro syndrome 1 AR [27]
RAB3GAP2 Warburg micro syndrome 2 AR [27]
RNF216 Cerebellar ataxia and hypogonadotropic hypogonadism AR [28]
SEMA3A Hypogonadotropic hypogonadism 16 with or without anosmia AD [29]
SOX2 Abnormalities of the central nervous system AD [30]
SPRY4 Hypogonadotropic hypogonadism 17 with or without anosmia AD [7]
STUB1 Spinocerebellar ataxia, autosomal recessive 16 AR [31]
TAC3 Hypogonadotropic hypogonadism 10 with or without anosmia AR [32]
TACR3 Hypogonadotropic hypogonadism 11 with or without anosmia AR [32]
TBC1D20 Warburg micro syndrome 4 AR [33]
WDR11 Hypogonadotropic hypogonadism 14 with or without anosmia AD [34]
This study was initiated after an owner reported a male cat with missing puberty characteristics,
such as normal testicle growth and change in primary dentition. The goal of this study was to identify
a possible underlying causative genetic defect.
2. Materials and Methods
2.1. Ethics Statement
All animal experiments were performed according to local regulations. The cat in this study is
privately owned and was examined with the consent of the owner. The “Cantonal Committee for
Animal Experiments” approved the collection of blood samples (Canton of Bern; permit 75/16).
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2.2. Animal Selection
A 3-year-old male domestic shorthair cat with testicular hypoplasia and a persistent primary
dentition was investigated. An EDTA blood sample was collected for genomic DNA isolation.
Additionally, we used 171 blood samples from cats of various breeds which had been donated to
the Vetsuisse Biobank (Table S1). These samples represented population controls without reports of
testicular hypoplasia or a persistent primary dentition.
2.3. Hormone Measurement
The testosterone level of the affected cat was measured from an EDTA blood sample by
labor-zentral.ch (Geuensee, Switzerland).
2.4. DNA Extraction
Genomic DNA was isolated from EDTA blood with the Maxwell RSC Whole Blood Kit using a
Maxwell RSC instrument (Promega). Additionally we used DNA from EDTA blood of 171 non-affected
control cats of various breeds that had been stored in our biobank.
2.5. Whole Genome Sequencing
An Illumina TruSeq PCR-free DNA library with 350 bp insert size of the affected cat (K532)
was prepared. We collected 168 million 2 × 150 bp paired-end reads on a NovaSeq 6000 instrument
(18x coverage). Mapping and alignment were performed as described [35]. The sequence data were
deposited under the study accession PRJEB7401 and the sample accession SAMEA5885924 at the
European Nucleotide Archive.
2.6. Variant Calling
Variant calling and filtering was performed as described [35]. To predict the functional effects of the
called variants, SnpEFF [36] software, together with NCBI annotation release 104 for the Felis_catus_9.0
assembly, was used. For variant filtering we used 38 control genomes, which were produced during
other projects of our group (Table S2).
2.7. Gene Analysis
We used the Felis_catus_9.0 cat reference genome assembly for all analyses. Numbering within
the feline TAC3 gene corresponded to the NCBI RefSeq accessions XM_003988924.5 (mRNA) and
XP_003988973.1 (protein).
2.8. Sanger Sequencing
The TAC3:c.220G>A variant was genotyped by direct Sanger sequencing of PCR amplicons.
A 400 bp PCR product was amplified from genomic DNA using AmpliTaqGold360Mastermix together
with primers 5‘-AGC CCA CTT CTC TTC CAG TG -3‘ (Primer F) and 5’-AGA GGG GAT TCA GGT
CAC AA-3’ (Primer R). After treatment with exonuclease I and alkaline phosphatase, amplicons




A 3-year-old male domestic shorthair cat was presented with persistent primary dentition
consisting of one primary maxillary canine (Figure 1). Upon examination there was one small
right testicle located in the scrotum. The left testicle could not be located. It was neither scrotal,
nor palpable in the inguinal area. The external genitalia, including the urethral orifice, were in the
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normal position, although with a juvenile appearance because of their small size. The hair coat had
an unkempt appearance. The cat had small body size but proportional growth. It had reportedly
displayed mounting behavior toward another female cat in the household and showed an increasingly
dominant–aggressive behavior toward other cats outside. The cat was presented for a follow-up
examination at 4 years of age. No changes in behavior or the stage of adolescence were noticed.
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Figure 1. Clinical phenotype characterized by persistent primary dentition and an “unkempt”
coat appearance.
3.2. Laboratory Findings
The blood testosterone level of the cat at the age of 4 years was 0.28 ng/mL, which was below the
reference range for cats (0.92 ng/mL–9.17 ng/mL).
3.3. Genetic Analysis
We sequenced the genome of the affected cat and searched for homozygous and heterozygous
variants in known candidate genes that were not present in 38 control cats of different breeds (Table 2).
Table 2. Results of variant filtering.
Filtering Step HomozygousVariants Heterozygous Variant
Private variants 25,355 209,967
Protein-changing private variants 111 756
Private variants in known candidate genes 1 0
This analysis identified a single homozygous private protein-changing variant in TAC3, a known
HH candidate gene [32]. The variant was designated as ChrB4:85,517,451C>T (Felis_catus_9.0
assembly). It is a missense variant, XM_003988924.5:c.220G>A, predicted to result in the amino
acid change XP_003988973.1:p.(Val74Met). This amino acid residue is moderately conserved across
mammals. Primates, including humans, have a threonine at this position, while all other investigated
mammalian TAC3 sequences have a valine (Figure 2). In silico predictions of the functional effect
yielded conflicting results. PolyPhen-2 predicted the variant as benign with a score of 0.147 [37]. SIFT
predicted that the variant affected protein function, with a score of 0.03 [38]. The SIFT prediction had
low confidence due to the limited diversity of the available related sequences.
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Figure 2. Multi-species protein alignment of the TAC3 precursor protein in the region of the missense
variant. The valine at position 74 of the feline TAC3 protein is conserved in most mammals, except
primates. The 10 amino acid sequence of the mature neurokinin B signaling peptide is indicated in red.
Amino acid sequen es were derived from XP_003988973.1 (cat); NP_037383.1 (human); XP_005625588.1
(dog); NP_851360. cattle); NP_033338.2 (mouse); NP_062035.1 (rat).
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We confirmed the presence of the TAC3 variant by Sanger sequencing and genotyped 171 control
cats (Figure 3). The case was homozygous for the mutant allele. Two domestic shorthair cats without
reports of testicular hypoplasia or persistent primary dentition carried the alternative allele in a
heterozygous state (Table 3; Table S1).
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Table 3. Genotype phenotype association of the TAC3:c.220G>A variant.
Cats G/G G/A A/A
ases (n = 1) 0 0 1
Control cats (n = 171) 169 2 0
4. isc ssi
In this tudy, we identified a TAC3:c.220G>A (p.Val74Met) missense variant in a domestic shorthair
cat with absent puberty characteristics, such as normal testicle gr wth and chan e in primary dentition.
The phenotype closely resembled HH, which belongs to the larger group of disorders of sexual
development (DSD). Th predicted amino acid substitution affects a moderately con erved region
of the TAC3 precursor protein, which is 11 residues away from the mature neurokinin B s quence.
The affected cat was homozygous for the mutant allele, which was fo nd to b rare in the normal cat
population. It should lso be noted that the variant is close to the exon/i tron boundary and might
have an effect on splicing. Due to a lack of suitable RNA samples, we could not experimentally assess
the TAC3 mRNA plicing pattern in the affected cat.
Cases of hu an have been reporte to be caused by variants in either the TACR3 gene
encoding the neurokinin B receptor or the TAC3 gene itself [32,39–43]. e enotype of these atients
is termed normosmic congenital hypogonadotropic hypogonadism (ncH ; OMI #614839). ncHH is
clinically characteriz d by a failure to n er puberty. Female pati nts have amenorrh a, abs nt breast
development, and hypoplastic varies and ut ri. Male patients have small testicles nd micropenis.
Body hair growth in ncHH patients resembles a juv nile pr -puberty state. ncHH in humans can be
successfully treated by p satil administration of GnRH [42] r steroid hormones [43]. The known
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human pathogenic TAC3 variants consist of frameshift [43] and splice site [41,42] variants and a single
missense variant, p.M90T, which affects the C-terminal residue of the mature neurokinin B peptide [32].
Additional likely pathogenic missense variants affecting the mature neurokinin B sequence were
deposited in the ClinVar database.
In felines, efforts are underway to develop a method to permanently sterilize cats by
RNAi-mediated silencing of KISS1 and TAC3. This method is predicted to lead to a reduction
in the stray animal population and therefore decrease animal suffering and vectors for human
disease [44].
5. Conclusions
Our genetic data and existing knowledge regarding the physiological function of TAC3 suggest
that the TAC3:c.220G>A (p.Val74Met) missense variant may be considered a candidate causative
variant for the observed HH phenotype in the studied cat. Given that this is a single case investigation
and that we have no functional confirmation of neurokinin B deficiency, this result must be considered
preliminary and should be interpreted with caution.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/10/806/s1,
Table S1: TAC3:c.220G>A genotypes of 172 cats from 13 different cat breeds; Table S2: Accession numbers of 39
cat genome sequences.
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